Results 121 to 130 of about 28,540 (254)

Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta‐analysis

HIV Medicine, Volume 26, Issue 8, Page 1184-1198, August 2025.
Abstract Objective This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Ishfaq Rashid, Nathan R. Unger, Connor Willis, Teerapon Dhippayom, Moti Ramgopal, Elizabeth M. Sherman, Nicholas Yared, Rachel Safran, Edwin Swiatlo, Amy R. Weinberg, Soodi Navadeh, Howard Weston Schmutz, Nathorn Chaiyakunapruk   +12 more
wiley   +1 more source

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase [PDF]

, 2000
Amy S. Espeseth, Peter J. Felock, Abigail Wolfe, Marc Witmer, Jay A. Grobler, Neville J. Anthony, Melissa S. Egbertson, Jeffrey Y. Melamed, Steve Young, Terence G. Hamill, James L. Cole, Daria J. Hazuda   +11 more
openalex   +1 more source

Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment‐experienced people living with HIV: A feasibility survey

HIV Medicine, Volume 26, Issue 8, Page 1251-1257, August 2025.
Abstract Introduction As life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug–drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART.
Marie Ballif, Manuela Correia da Silva Saúde, David Haerry, Marcel Stoeckle, Patrick Schmid, Dominique Braun, Alexandra Calmy, Gilles Wandeler, Bernard Surial   +8 more
wiley   +1 more source

Brief Histories of Retroviral Integration Research and Associated International Conferences

Viruses
The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj   +1 more source

Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism

Brazilian Journal of Pharmaceutical Sciences, 2011
From the identification of HIV as the agent causing AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research over the past twenty-six years have been formidable.
Carolina Horta Andrade, Lenis Medeiros de Freitas, Valéria de Oliveira   +2 more
doaj   +1 more source

HIV-1 Protease Inhibitors From Marine Brown Alga: A Literature Review [PDF]

, 2017
The human immunodeficiency virus type 1 (HIV-1) causes an infectious disease that if left untreated can progress to acquired immunodeficiency syndrome (AIDS) and be fatal.
Nunez Aguilar, Eric
core   +1 more source

A New Class of HIV-1 Integrase Inhibitors: The 3,3,3‘,3‘-Tetramethyl-1,1‘-spirobi(indan)-5,5‘,6,6‘-tetrol Family [PDF]

, 2000
Valentina Molteni, Denise Rhodes, Kathleen Rubins, Mark Hansen, Frederic D. Bushman, Jay S. Siegel   +5 more
openalex   +1 more source

Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV

HIV Medicine, Volume 26, Issue 8, Page 1267-1288, August 2025.
Abstract Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking. Integrase inhibitor (INI) resistance may limit future therapy.
Kyle Ring, Alexa Elias, Megan Devonald, Melanie Smuk, Chloe Orkin   +4 more
wiley   +1 more source

Factors mediating and associated with immunological response in women living with HIV in Sweden: A nationwide register‐based study

HIV Medicine, Volume 26, Issue 8, Page 1311-1316, August 2025.
Abstract Introduction Women remain underrepresented in studies on immunological response (IR) among virally suppressed people living with HIV. Despite receiving antiretroviral therapy (ART) some individuals do not attain an IR, increasing their risk of non‐AIDS morbidity and mortality.
Josefin Nilsson, Olof Elvstam, Erik Sörstedt, Philippe Wagner, Piotr Nowak, Johanna Brännström, Christina Carlander   +6 more
wiley   +1 more source

Effectiveness of switching to doravirine‐based antiretroviral therapy: A real‐world study in Germany

HIV Medicine, Volume 26, Issue 8, Page 1289-1299, August 2025.
Abstract Objectives Doravirine (DOR)‐based antiretroviral therapy (ART) has been shown in clinical trials to be effective and well tolerated in treating HIV‐1. The EffectiVeness of SwItChing to DORavirine‐based Antiretroviral Therapy (VICDOR) study characterized the use, effectiveness and impact on body weight and lipids of DOR‐based ART in a ...
Christoph Wyen, Michael Sabranski, Celia Jonsson‐Oldenbüttel, Johannes Bogner, Heribert Knechten, Stefan Esser, Nazifa Qurishi, Sven Schellberg, Irina Kolobova, Jann‐Patrick Pelz, Yohance O. Whiteside, Bekana K. Tadese, Jürgen K. Rockstroh   +12 more
wiley   +1 more source